Particle.news

Download on the App Store

FDA Targets Unapproved Kratom-Derived Opioid Compound in Seven Warning Letters

Companies have 15 business days to prove they have halted the illicit marketing of 7-hydroxymitragynine products.

Image
Image
Image
Image

Overview

  • The FDA issued warning letters to seven firms, including Shaman Botanicals LLC and My Smoke Wholesale, for selling products with added or elevated levels of 7-hydroxymitragynine.
  • Targeted items encompass tablets, gummies, drink mixes and shots marketed as supplements or foods through online retailers, smoke shops and gas stations.
  • 7-hydroxymitragynine is a potent mu-opioid agonist occurring naturally in kratom but is not approved for dietary supplements, conventional foods or any regulated drug.
  • The agency cautioned that consumers using these unapproved products may be exposing themselves to substances that lack evidence of safety or effectiveness.
  • Failure to satisfy the 15-day compliance deadline could prompt further enforcement actions, such as product seizures or injunctions.